Smith & Nephew SNATS (NYSE:SNN) Sets New 52-Week Low - Should You Sell?

Key Points

• Smith & Nephew SNATS fell to a new 52-week low of $26.38, below its prior close of $26.96 and its 50- and 200-day moving averages.
• Analyst sentiment is broadly cautious: the stock has a consensus “Hold” rating from MarketBeat, with 10 Holds, one Buy and one Sell, and an average price target of $31.91.
• The company announced a $0.312-per-share dividend payable November 6 to shareholders of record October 2, while institutional investors own approximately 25.64% of the stock.

Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) reached a new 52-week low during trading on Thursday. The company traded as low as $26.38 and last traded at $26.4550, with a volume of 588841 shares changing hands. The stock had previously closed at $26.96.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on SNN shares. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Smith & Nephew SNATS in a research note on Thursday, August 6th. Zacks Research upgraded Smith & Nephew SNATS from a "strong sell" rating to a "hold" rating in a report on Tuesday, September 8th. Barclays cut Smith & Nephew SNATS from an "equal weight" rating to an "underweight" rating in a research report on Wednesday, August 5th. Kepler Capital Markets lowered Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research report on Thursday, June 4th. Finally, Wall Street Zen raised Smith & Nephew SNATS from a "hold" rating to a "buy" rating in a research report on Sunday, September 13th. One analyst has rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $31.91.

Smith & Nephew SNATS Stock Performance

The business has a 50-day moving average price of $29.14 and a 200-day moving average price of $30.42. The company has a current ratio of 2.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62.

Smith & Nephew SNATS Announces Dividend

The firm also recently announced a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be given a dividend of $0.3120 per share. This represents a yield of 205.0%. The ex-dividend date of this dividend is Friday, October 2nd.

Institutional Investors Weigh In On Smith & Nephew SNATS

Several institutional investors have recently added to or reduced their stakes in SNN. Clearstead Trust LLC purchased a new position in shares of Smith & Nephew SNATS in the 2nd quarter valued at approximately $25,000. Addison Advisors LLC acquired a new position in Smith & Nephew SNATS during the 2nd quarter valued at approximately $43,000. Allworth Financial LP purchased a new position in shares of Smith & Nephew SNATS in the second quarter worth $48,000. Centaurus Financial Inc. purchased a new position in Smith & Nephew SNATS in the 2nd quarter worth $112,000. Finally, Global Retirement Partners LLC raised its stake in shares of Smith & Nephew SNATS by 811.6% in the fourth quarter. Global Retirement Partners LLC now owns 1,887 shares of the medical equipment provider's stock worth $62,000 after purchasing an additional 1,680 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company's stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company headquartered in Watford, England. Founded in 1856 by pharmacist Thomas James Smith in Hull, the company has grown from a pharmacy business into a provider of surgical and wound-care products for healthcare professionals and patients.

The company operates through three principal areas: Orthopaedics, Sports Medicine, and Advanced Wound Management. Its products include joint-replacement systems, trauma and extremity devices, arthroscopy equipment, surgical repair technologies, wound dressings, negative-pressure wound therapy systems, and other products used to support healing and tissue recovery.

Smith & Nephew serves hospitals, clinics, surgeons, and patients in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific, and other international regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.